Akoya Biosciences, Inc. Contracts & Agreements

Separation Agreement and Release, dated July 3, 2023, by and between the Company and Marilee Moy (Filed With SEC on July 5, 2023)

Separation Agreement and Release, dated June 27, 2023, by and between the Company and Dr. Ehab El-Gabry (Filed With SEC on June 28, 2023)

Underwriting Agreement, dated as of June 7, 2023 among Akoya Biosciences, Inc., Morgan Stanley & Co. LLC and Piper Sandler & Co (Filed With SEC on June 12, 2023)

Offer Letter, dated January 30, 2023, by and between the Registrant and Johnny Ek (Filed With SEC on May 9, 2023)

Offer Letter, dated January 31, 2023, by and between the Registrant and Jennifer Kamocsay (Filed With SEC on May 9, 2023)

Amendment No. 1 to Credit and Security Agreement, dated March 21, 2022, by and between the Registrant and Midcap Financial Trust (Filed With SEC on August 9, 2022)

Offer Letter, dated April 1, 2022, by and between Registrant and Ehab El-Gabry (Filed With SEC on August 9, 2022)

Amendment No. 2 to Credit and Security Agreement, dated June 1, 2022, by and among Akoya Biosciences, Inc. and Midcap Financial Trust, as agent, and the lenders party thereto (Filed With SEC on June 2, 2022)

Akoya Biosciences, Inc. Executive Severance Plan (Filed With SEC on March 29, 2022)

Form of Underwriting Agreement (Filed With SEC on April 12, 2021)

Akoya Biosciences, Inc. 2021 Equity Incentive Plan and form of stock option agreement thereunder (Filed With SEC on April 12, 2021)

Akoya Biosciences, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on April 12, 2021)

Offer Letter, dated March 2, 2021, including a Letter Amendment dated March 16, 2021, by and (Filed With SEC on April 12, 2021)

Akoya Biosciences, Inc. 2015 Equity Incentive Plan, as amended, and form of stock option agreement thereunder (Filed With SEC on March 26, 2021)

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on March 26, 2021)

Offer Letter, dated June 28, 2017, by and between the Registrant and Brian McKelligon (Filed With SEC on March 26, 2021)

Letter Amendment, dated October 8, 2018, by and between the Registrant and Brian McKelligon (Filed With SEC on March 26, 2021)

Offer Letter, dated January 28, 2019, by and between the Registrant and Joseph Driscoll (Filed With SEC on March 26, 2021)

Offer Letter, dated July 14, 2020, by and between the Registrant and Niroshan Ramachandran (Filed With SEC on March 26, 2021)

Exclusivity (Equity) Agreement, dated November 17, 2015, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University (Filed With SEC on March 26, 2021)

Amendment No. 1 to the License Agreement, dated November 18, 2016, by and between the Registrant and The Board of Trustees of the Leland Stanford Junior University (Filed With SEC on March 26, 2021)

License and Royalty Agreement, dated September 28, 2018, by and among the Registrant, PerkinElmer Health Sciences, Inc., Cambridge Research & Instrumentation, Inc. and VisEn... (Filed With SEC on March 26, 2021)

Transition Services Agreement, dated September 28, 2018, by and between the Registrant and PerkinElmer Health Sciences, Inc., as amended by First Amendment to the Transition... (Filed With SEC on March 26, 2021)

Exclusive Patent License Agreement, dated June 26, 2018, by and between the Registrant and the University of Washington (Filed With SEC on March 26, 2021)

Credit and Security Agreement, dated October 27, 2020, by and between the Registrant and Midcap Financial Trust (Filed With SEC on March 26, 2021)

Amended and Restated Investors Rights Agreement, dated September 27, 2019, by and among the Registrant and certain of its stockholders (Filed With SEC on March 26, 2021)

Offer Letter, dated March 2, 2021, by and between Registrant and Frederic Pla (Filed With SEC on March 26, 2021)